+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 12 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are comparing two treatment combinations for adults with advanced nonsquamous non-small cell lung cancer NSCLC that is stage IV or advanced stage IIIBC, specifically with a KRAS p.G12C mutation and no PD-L1 expression. The study evaluates progression-free survival and overall survival between participants receiving sotorasib with chemotherapy and those receiving pembrolizumab with chemotherapy. This is a phase 3, randomized, open-label study aiming to find which frontline therapy might better manage this type of lung cancer. Participants are randomly assigned to one of two groups one group receives sotorasib orally combined with carboplatin and pemetrexed chemotherapy, and the other group receives pembrolizumab given intravenously combined with the same chemotherapy agents. Treatments are given as front-line therapy for their cancer. The study measures the effects of these combinations over time, including tumor response and quality of life changes. During the study, participants will be closely monitored for progression-free survival, overall survival, and other outcomes related to tumor response and quality of life through questionnaires. Researchers will track treatment-emergent adverse events, vital signs, and lab tests to evaluate safety. The study includes follow-up assessments for up to approximately 5.5 years, allowing comprehensive evaluation of long-term outcomes and side effects. Participant involvement includes regular visits for treatment administration and assessments throughout the study period.

Age: 18Years - 100YearsAll GendersPhase 3
424 locations
C

Actively Recruiting

Researchers are evaluating camizestrant compared to standard endocrine therapy in patients with ER-positive, HER2-negative early breast cancer who have an intermediate or high risk of disease recurrence. This Phase III open-label study includes patients who have completed definitive locoregional therapy, with or without chemotherapy, and have received standard adjuvant endocrine therapy for at least 2 years and up to 5 years. The study aims to determine if camizestrant improves invasive breast cancer-free survival and other important outcomes over a long-term follow-up. Participants will be randomly assigned to receive either camizestrant orally or continue standard endocrine therapy chosen by their doctor, which may include aromatase inhibitors like exemestane, letrozole, anastrozole, or tamoxifen. Treatment in both groups will last for up to 60 months. The study allows prior use of CDK46 inhibitors and includes an open-label design where both participants and researchers know the assigned treatment. During the study, participants will be monitored with assessments including survival outcomes, disease-free survival, relapse-free survival, and overall survival for up to 10 years from the last patient randomized. Safety will be tracked through adverse event reporting, laboratory and vital signs tests, and symptom questionnaires measuring arthralgia, hot flushes, vaginal dryness, and quality of life. Pharmacokinetics will be studied up to 6 months after treatment starts. The total duration of participation can extend over many years to capture long-term results.

Age: 18Years - 130YearsAll GendersPhase 3
709 locations
A

Actively Recruiting

Researchers are evaluating the effects of AZD6793 in adults with moderate to very severe chronic obstructive pulmonary disease COPD. This Phase IIb study compares two different doses of AZD6793 to placebo tablets to assess their efficacy and safety. The study is randomized, double-blind, placebo-controlled, and involves about 970 participants worldwide. Participants will be randomly assigned to one of three groups two different doses of AZD6793 or a matching placebo. The study lasts for 24 weeks, during which participants will take oral tablets of their assigned treatment. The trial aims to measure how well AZD6793 works to reduce COPD exacerbations compared to placebo. Throughout the study, participants will have regular assessments including lung function tests, symptom questionnaires, and blood tests to measure drug levels. Researchers will monitor the rate of COPD exacerbations, lung function changes, and symptom scores over 24 weeks. Safety and tolerability of the treatments will also be closely observed during this period.

Age: 40Years +All GendersPhase 2
367 locations
E

Actively Recruiting

Researchers are studying adults newly diagnosed with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancers who are starting systemic cancer treatments such as chemotherapy or immune checkpoint inhibitors. The purpose is to understand how cannabis and cannabinoid use relates to cancer-related symptoms over one year. This observational study enrolls 2000 participants to explore these associations in community oncology settings. Participants do not receive any experimental treatments but complete surveys and have their medical records reviewed. Assessments occur monthly for up to 12 months, capturing cannabis use, perceived benefits and harms, and adverse effects alongside symptom tracking. There is an optional sub-study for some participants receiving immune checkpoint inhibitors at specific cancer centers. During the study, participants complete monthly surveys either online at home, in clinic, or other locations, and their medical records are reviewed for treatment and symptom information. Researchers measure cancer-related symptoms and cannabis use patterns over time. The study monitors participants for up to one year to evaluate symptom changes and cannabis-related effects, with no intervention administered by the study team.

Age: 18Years +All Genders
491 locations
T

Actively Recruiting

Healthy Volunteer

This research aims to better understand outcomes of quitting e-cigarettes in adults who also use cannabis. It focuses on how cannabis and tobacco interact during quitting attempts using varenicline, a medication approved for cigarette cessation but not for e-cigarette cessation. The study targets adults aged 18 to 40 who use both e-cigarettes and cannabis, regardless of their interest in quitting cannabis. The trial is conducted at three sites in South Carolina. Participants receive a 12-week treatment with varenicline following a standard dose schedule starting from 0.5 mg once daily and increasing to 1.0 mg twice daily, maintained for 11 weeks. Alongside medication, participants receive psychosocial counseling and financial incentives each week based on verified abstinence from e-cigarettes using urinary cotinine tests. This approach combines medication, behavioral support, and incentives. During the study, participants will attend weekly visits for assessments including urine tests to confirm tobacco abstinence and cannabis use. Researchers will track changes in cannabis use during the treatment and evaluate the impact of cannabis use severity on quitting success. The main outcome measured is 7-day tobacco abstinence at the end of 12 weeks. The total study duration per participant is 12 weeks, with monitoring throughout this period.

Age: 18Years - 40YearsAll GendersPhase 4
3 locations
E

Actively Recruiting

Researchers are studying younger breast cancer survivors who experience elevated depressive symptoms to compare digital mindfulness meditation programs. This phase III clinical trial evaluates two digital methods a live instructor-led program over Zoom and a self-paced app-based program. The study aims to find which digital approach best improves mental health and well-being after completing primary cancer treatment. Participants are randomly assigned to one of three groups a live online mindfulness group meeting weekly for six weeks via Zoom a self-paced app-based mindfulness program with lessons and exercises unlocked sequentially or a meditation-only control group using guided audio meditations. All participants will have access to the mindfulness meditation app throughout the study, including six months of follow-up. Devices and internet access are provided to those who need them. During the study, participants will attend group sessions or use the app according to their assigned group and complete daily mindfulness practice. Researchers will track engagement and measure depressive symptoms at two weeks, three to six months, and six months after the intervention. They will also assess fatigue and explore factors influencing treatment effects and cost-effectiveness. The total study duration spans the six-week intervention plus six months of follow-up.

Age: 18Years - 50YearsAll GendersPhase 3
456 locations
S

Actively Recruiting

Researchers are studying the effects of lunsekimig, given as a subcutaneous injection, in adults aged 40 to 80 years with chronic obstructive pulmonary disease COPD that is not well controlled and characterized by an eosinophilic phenotype. This Phase 2bPhase 3, randomized, double-blind, placebo-controlled study compares two dosing regimens of lunsekimig against placebo to evaluate its efficacy, safety, and tolerability over a prolonged period. Participants will be randomly assigned to one of three groups lunsekimig dose regimen A, lunsekimig dose regimen B, or a matching placebo. They will receive subcutaneous injections during a treatment period of about 48 weeks. The study includes a screening phase lasting up to 4 weeks before treatment, followed by an 8-week follow-up after the intervention, totaling up to 60 weeks of participation. During the trial, participants will undergo regular assessments including lung function tests, symptom questionnaires like the Chronic Airways Assessment Test CAAT, and monitoring of exacerbations and adverse events. Researchers will measure the rate of moderate to severe COPD exacerbations as the primary outcome. Safety labs, antibody testing, and drug concentration monitoring will also occur. Participants will be monitored throughout the study duration, including follow-up after treatment ends.

Age: 40Years - 80YearsAll GendersPhase 3
314 locations
R

Actively Recruiting

Healthy Volunteer

This research aims to evaluate whether adding system-level changes to the kidney transplant process can improve how quickly patients start transplant evaluations. The study focuses on addressing barriers in the referral and evaluation steps for patients with end-stage renal disease or kidney disease who are referred for transplantation at five large transplant centers. It is led by Indiana University and involves multiple centers in Georgia, North Carolina, South Carolina, and Indiana. The intervention includes several components transplant centers will receive detailed performance feedback reports on referral and evaluation closures, contact patients using their preferred communication methods, make phone calls to dialysis facilities during patient sessions, and reach out to referring or other healthcare providers if needed. They will also use a secure web-based platform or email to share patient status updates and track all communication efforts before closing referrals. Dialysis centers will participate in an awareness campaign to support these activities. Participants will be involved through their referral to transplant centers, where researchers will monitor the start of transplant evaluations within six months of referral. They will also track changes in waitlisting and transplant receipt over up to one year post-intervention. The study includes ongoing monitoring of referral closures and patient contacts to assess the interventions impact on improving access to kidney transplantation. The total participation period varies depending on referral and evaluation timing.

Age: 18Years - 80YearsAll GendersPhase Not Applicable
5 locations
P

Actively Recruiting

Researchers are evaluating the efficacy and safety of iptacopan LNP023 in people aged 12 to 60 years with idiopathic immune complex-mediated membranoproliferative glomerulonephritis IC-MPGN. This Phase III, multicenter, randomized, double-blind, placebo-controlled study aims to examine whether iptacopan can reduce protein in the urine and improve kidney function compared to placebo. The study also looks at changes in patient-reported fatigue. IC-MPGN is linked to problems with the alternative complement pathway, which affects disease progression. Participants will receive either iptacopan 200 mg twice daily or a matching placebo, both given alongside standard care. Adolescents receive adjusted doses 2x100 mg b.i.d., while adults receive 200 mg b.i.d. The study includes a double-blind treatment period lasting 18 months. After this period, participants can either stop iptacopan and enter a 30-day safety follow-up or continue iptacopan treatment in an open-label extension study. During the study, participants will undergo regular urine collections to measure protein levels, kidney function tests eGFR, and assessments of fatigue using a patient questionnaire. Researchers will monitor safety through vital signs, ECGs, laboratory tests, and heart function parameters. The total participation lasts up to 18 months with additional safety follow-up or extension treatment options afterward.

Age: 12Years - 60YearsAll GendersPhase 3
131 locations
E

Actively Recruiting

Researchers are conducting a Phase III international study to evaluate the effects of balcinrenone combined with dapagliflozin compared to dapagliflozin alone in patients with chronic heart failure HF and impaired kidney function who have recently experienced a heart failure event. The study aims to assess the impact of these treatments on cardiovascular death and heart failure events, including hospitalizations and other HF-related episodes. Participants are randomly assigned to one of three groups one receiving balcinrenonedapagliflozin 15 mg10 mg capsule plus placebo another receiving balcinrenonedapagliflozin 40 mg10 mg capsule plus placebo and a third group receiving dapagliflozin 10 mg tablet plus placebo capsule. All treatments are given once daily orally, alongside standard care for heart failure and kidney impairment. The study is conducted across approximately 700 sites in about 40 countries. During the trial, participants will be monitored over approximately 36 months for cardiovascular death, heart failure hospitalizations, and heart failure events without hospitalization. Assessments include heart failure symptom scores measured at 24 weeks post-randomization. Researchers will also track total occurrences of cardiovascular and heart failure events, as well as overall mortality. This long-term follow-up aims to evaluate treatment effects on these important health outcomes.

Age: 18Years - 130YearsAll GendersPhase 3
852 locations

1-10 of 12

1